Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Jan 19, 2017
http://dicerna.com/ SCN's Jane King interviews Douglas M. Fambrough, Ph.D., President & CEO of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA). They discuss the biopharmaceutical company and its exciting proprietary drug platform GalXC™ Dicerna is an RNA interference-based biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver and for other therapeutic areas in which the liver plays a key role including cardiovascular disease, chronic liver diseases, and liver infectious diseases. • Their proprietary RNAi technology uses the body’s natural biological pathways to silence or “turn off” genes with a high degree of selectivity and specificity.